XML 33 R23.htm IDEA: XBRL DOCUMENT
v3.25.1

Summary of Significant Accounting Policies Summary of Significant Accounting Principles (Tables) | 9 Months Ended
--- | ---
Mar. 31, 2025
Accounting Policies [Abstract] |
Schedule of Other Nonoperating Income (Expense) | The following table summarizes the components of other (expense) income, net.
| Three Months Ended March 31, |  | Nine Months Ended March 31,
| 2025 |  | 2024 |  | 2025 |  | 2024 |  |
(Losses) gains on derivatives not designated as hedging instruments (1) | $ | (14,640) |  |  | $ | 9,071 |  |  | $ | (1,577) |  |  | $ | 3,715 |  |  |
Currency-related gains (losses), net (2) | 5,131 |  |  | (12,434) |  |  | 11,691 |  |  | (2,071) |  |  |
Other gains (losses) | 68 |  |  | (288) |  |  | 631 |  |  | 733 |  |  |
Total other (expense) income, net | $ | (9,441) |  |  | $ | (3,651) |  |  | $ | 10,745 |  |  | $ | 2,377 |  |  |
_____________________ (1) Includes realized and unrealized gains and losses on derivative currency forward and option contracts not designated as hedging instruments. For contracts not designated as hedging instruments, we realized gains of $4,434 and $5,183 for the three and nine months ended March 31, 2025, respectively, and losses of $349 and $838 for the three and nine months ended March 31, 2024, respectively. Refer to Note 4 for additional details relating to our derivative contracts. (2) Currency-related gains (losses), net primarily relates to significant non-functional currency intercompany financing relationships that we may change at times and are subject to currency exchange rate volatility. In addition, during the three and nine months ended March 31, 2024, we recognized gains of $1,748 and $1,454, respectively, on a cross-currency swap designated as a cash flow hedge which hedges the remeasurement of an intercompany loan. We did not hold any cross-currency swap contracts that were designated as cash flow hedges during the three and nine months ended March 31, 2025. Refer to Note 4 for additional details regarding our cash flow hedges.
Schedule of Weighted Average Number of Shares | The following table sets forth the reconciliation of the weighted-average number of ordinary shares.
| Three Months Ended March 31, |  | Nine Months Ended March 31,
| 2025 |  | 2024 |  | 2025 |  | 2024 |  |
Weighted average shares outstanding, basic | 24,834,409 |  |  | 26,216,216 |  |  | 24,990,419 |  |  | 26,432,423 |  |  |
Weighted average shares issuable upon exercise/vesting of outstanding share options/PSUs/RSUs/warrants (1)(2) | — |  |  | — |  |  | 851,362 |  |  | 711,196 |  |  |
Shares used in computing diluted net (loss) income per share attributable to Cimpress plc | 24,834,409 |  |  | 26,216,216 |  |  | 25,841,781 |  |  | 27,143,619 |  |  |
Weighted average anti-dilutive shares excluded from diluted net (loss) income per share attributable to Cimpress plc (1)(2) | 2,083,040 |  |  | 955,594 |  |  | 312,874 |  |  | 127,229 |  |  |
__________________ (1) In the periods in which a net loss is recognized, the impact of share options, PSUs, RSUs and warrants is excluded from shares used in computed diluted net loss per share as it is anti-dilutive. (2) On May 1, 2020, we entered into a financing arrangement which included 7-year warrants to purchase 1,055,377 of our ordinary shares with a strike price of $60 that have a potentially dilutive impact on our weighted average shares outstanding. For the three months ended March 31, 2025, the average share price was below the strike price for the quarter; therefore, the total outstanding warrants were considered anti-dilutive. The weighted average anti-dilutive effect of the warrants for the three months ended March 31, 2025 and 2024 was 1,055,377 and 309,000 (anti-dilutive due to our net loss position), respectively, and the weighted average dilutive effect of the warrants for the nine months ended March 31, 2025 and 2024 was 196,438 and 184,608, respectively.

X
- References No definition available. + Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items. + References No definition available. + Details
Name: | us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration